Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$2.59B in Q4 2024 → $170M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Allogene Therapeutics Inc | 27.5% | Unchanged | 22,032,040 | $46.9M |
| Celcuity Inc | 17.3% | Unchanged | 295,652 | $29.6M |
| Arvinas Inc | 16.2% | Unchanged | 3,457,815 | $27.7M |
| Pyxis Oncology Inc | 11.4% | Unchanged | 7,032,770 | $19.5M |
| Wave Life Sciences Ltd | 6.4% | Unchanged | 1,875,000 | $10.9M |
| Biohaven Ltd | 4.7% | Unchanged | 505,645 | $8M |
| Caribou Biosciences Inc | 4.6% | Unchanged | 4,690,431 | $7.88M |
| Spero Therapeutics Inc | 3.1% | Unchanged | 2,362,348 | $5.34M |
| Zentalis Pharmaceuticals Inc | 2.3% | Unchanged | 953,834 | $3.85M |
| Oric Pharmaceuticals Inc | 2.1% | Trimmed 92% | 372,904 | $3.55M |
| Cardiff Oncology Inc | 1.8% | Unchanged | 2,411,575 | $3.01M |
| Zura Bio Ltd | 1.7% | Trimmed 81% | 538,841 | $2.88M |
| Agomab Therapeutics Nv | 0.6% | Unchanged | 75,000 | $1.04M |
| Bolt Biotherapeutics Inc | 0.1% | Unchanged | 31,305 | $134K |
| Nextcure Inc | 0.0% | Trimmed 71% | 44,347 | $73K |
| Ginkgo Bioworks Holdings Inc | 0.0% | Unchanged | 2,928 | $30K |
| SH Senseonics Hldgs Inc | 0.0% | Unchanged | 2,171 | $12.4K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed August 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Oric Pharmaceuticals Inc | Trimmed | −4,407,497 | −$42M | 2.1% |
| Zura Bio Ltd | Trimmed | −2,300,072 | −$12.3M | 1.7% |
| Q32 Bio Inc | Exited | −101,618 | −$737K | — |
| Nextcure Inc | Trimmed | −109,007 | −$179K | — |
quarter ended March 31, 2026 · filed May 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Oric Pharmaceuticals Inc | Trimmed | −595,943 | −$7.19M | 24.1% |
| Celcuity Inc | Trimmed | −53,754 | −$5.7M | 13.1% |
| Q32 Bio Inc | Trimmed | −176,159 | −$1.28M | 0.3% |
| An2 Therapeutics Inc | Exited | −715,295 | −$815K | — |
| Agomab Therapeutics Nv | New | +75,000 | +$814K | 0.3% |
| Zura Bio Ltd | Trimmed | −131,109 | −$777K | 7.1% |
| Nextcure Inc | Trimmed | −4,292 | −$43K | 0.6% |
quarter ended December 31, 2025 · filed February 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Biontech Se | Exited | −1,658,361 | −$164M | — |
| Tourmaline Bio Inc | Exited | −1,272,214 | −$60.8M | — |
| Essa Pharma Inc | Exited | −1,675,000 | −$320K | — |
| SH Senseonics Hldgs Inc | Trimmed | −41,255 | −$228K | — |
quarter ended September 30, 2025 · filed November 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Biontech Se | Trimmed | −2,000,000 | −$197M | 37.4% |
| Nextcure Inc | New | +157,646 | +$924K | 0.2% |
| Nextcure Inc | Exited | −157,646 | −$870K | — |
quarter ended June 30, 2025 · filed August 11, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Nextcure Inc | Trimmed | −1,734,117 | −$9.57M | 0.2% |
| Bolt Biotherapeutics Inc | Exited | −626,109 | −$250K | — |
| Bolt Biotherapeutics Inc | New | +31,305 | +$181K | — |
quarter ended March 31, 2025 · filed May 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Haleon PLC | Exited | −197,228,952 | −$1.88B | — |
| Akero Therapeutics Inc | Exited | −562,626 | −$15.7M | — |
| Nextcure Inc | Added | +433,213 | +$208K | 0.2% |
Loading...
